
Literatur

1. Adamczak M, Gross ML, Krtil J, et al.: Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotaly nephrectomized rats. *J Am Soc Nephrol* 14: 2833-2842, 2003
2. Alt JM, Deerberg F, Hackbarth HJ, Stolte H: The study of urinary protein excretion in male rats as compared with human proteinuria. *Contribut Nephrol* 19: 79-87, 1980
3. Amann K, Tyralla K, Gross ML, et al.: Cardiomyocyte loss in the experimental renal failure: Prevention by ramipril. *Kidney Int* 63:1708-13, 2003
4. D'Amico G, Bazzi C: Pathophysiology of proteinuria. *Kidney Int* 63: 809-825, 2003
5. Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. *L Clin Invest* 76: 512-619, 1985
6. Barker DJP: Intrauterine programming of fetal disease. *Brit Med J* 1: 418-423, 1995
7. Barker DJP, Bagby SP: Developmental antecedents of cardiovascular disease. A historical perspective. *J Am Nephrol*: 2537-44, 2005
8. Barker DJP, Osmond C, Golding J, Kuh D, Wadsworth ME: Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. *BMJ* 298: 564-567, 1989
9. Benigni A, Perico N, Remuzzi G: Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression. *Curr Op Nephrol Hypertens* 10: 1-6, 2001
10. Bennett CM, Glasscock RJ, Chang RL, et al.: Permselectivity of the glomerular capillary wall. Studies of experimental glomerulonephritis in the rat using dextran sulfate. *J Clin Invest* 57: 1287-94, 1976
11. Bennett PH, Haffner S, Kasiske BL, et al.: Screening and management of microalbuminuria in patients with diabetes mellitus: Recommendations to the scientific advisory board of the national kidney foundation from an ad hoc committee of the council on diabetes mellitus of the national kidney foundation. *Am J Kidney Dis* 25: 107-112, 1995
12. Bianchi S, Bigazzi R, Campese VM: Microalbuminuria and essential hypertension. *J Nephrol* 10: 216-218, 1997
13. Bianchi G, Cusi D, Gatti M, et al.: A renal abnormality as a possible cause of "essential" hypertension. *Lancet* 1: 173-7, 1979

14. Bianchi G, Fox U, Di Franchesco GF, Giovanetti AM, Pagetti D: Blood pressure changes produced by kidney cross-transplantation between spontaneously hypertensive rats and normotensive rats. *Clin Sci Mol Med* 47: 435-48, 1974
15. Bidani AK, Schwartz MM, Lewis EJ: Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. *Am J Physiol* 252: F1003-F1010, 1987
16. Bigazzi R, Bianchi S, Baldari D, Campese VM: Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. *J Hypertens* 16:1325-1333, 1998
17. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 72: 248-54, 1976
18. Breeds DK, Hutchinson FN, Cole GJ, Williams JC: Differential effects of diabetes and glomerulonephritis on glomerular basement membrane composition. *J Am Soc Nephrol* 3: 755, 1992
19. Brenner BM: Nephron adaptation to renal injury or ablation. *Am J Physiol* F324-37, 1985
20. Brenner BM, Chertow GM: Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. *AM J Kidney Dis* 23: 171-175, 1994
21. Brenner BM, Garcia DL, Anderson S: Glomeruli and blood pressure: More of one, less the other? *Am J Hypertens* 1: 335-47, 1988
22. Brenner BM, Mackenzie HS: Nephron mass as a risk factor for progression of renal diseases. *Kidney Int Suppl* 63: 124-7, 1997
23. Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: The role of haemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal kidney disease. *N Engl J Med* 307: 652-659, 1982
24. Bricker DJ: On the meaning of the intact nephron hypothesis. *Am J Med* 4: 1-11, 1969
25. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S: Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. *Am J Kidney Dis* 30: 659-64, 1997
26. da Costa S, Albuquerque ZP: Experimental models of chronic renal failure. *Nephron* 20: 297-98, 1978
27. Chauntin A, Ferris E. Experimental renal insufficiency produced by partial nephrectomy. *Arch Intern Med* 49: 767, 1932

28. Clausen P, Feldt-Rasmussen B, Jensen G, Jensen JS: Endothelial haemostatic factors are associated with progression of urinary albumin excretion in clinically healthy subjects: A 4-year prospective study. *Clin Sci(Lond)* 97: 37– 43, 1999
29. Curtis JJ, Luke RG, Dustan HP, et al.: Remission of essential hypertension after renal transplantation. *N Engl J Med* 309: 1009-15, 1983
30. Davies DJ, Brewer DB: Irreversible glomerular damage following heterologous serum albumin. *J Pathol* 123: 45-52, 1977
31. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A: Albuminuria reflects widespread vascular damage: The Steno hypothesis. *Diabetologia* 32: 219 -226, 1989
32. Deckert T, Yokoyama H, Mathiesen E, et al.: Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes. *BMJ* 312: 871-874, 1996
33. Deen WM, Maddox DA, Robertson CR, Brenner BM: Dynamics of glomerular ultrafiltration in the rat. VII. Response to reduced renal mass. *Am J Physiol* 227: 556-562, 1974
34. Dunnill MS, Halley W: Some observations on the quantitative anatomy of the kidney. *J Path* 110: 113-121, 1973
35. European Society of Hypertension - European Society of Cardiology Guidelines Committee: 2003 European society of hypertension - -european society of cardiology guidelines for management of arterial hypertension. *J Hypertens* 21: 1011-1053, 2003
36. Fassi A, Sangali F, Maffi R, et al: Progressive glomerular injury in the WMF rats is predicted by inborn nephron deficit. *Am Soc. Nephrol* 9: 1399-1406, 1998
37. Forman JP, Brenner BM: "Hypertension" and "microalbuminuria": The bell tolls for thee. *Kidney Int* 69: 22-28, 2006
38. Gerstein HC, Mann JF, Pogue J, et al., for the HOPE study investigators: Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. *Diabetes Care* 23(suppl 2): B35–B39, 2000
39. Goldblatt H, Lynch J, Hanzal RF, Summerville WW: Studies on experimental hypertension. I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. *J Exp Med* 59: 347-379, 1934
40. Greaves SC: Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. *Am J Kindey Dis* 24: 768-76, 1994
41. Greger R: Regulation der Nierendurchblutung. In: Deetjen P, Speckmann EJ: *Physiologie*. 3. Auflage, München, Deutschland, Urban&Fischer: 376-78, 1999

42. Gretz N, Strauch M.: Experimental and genetic rat models of chronic renal failure. Basel, Schweiz: Karger AG: 1-26, 1993
43. Gschwend S, Buikema H, Navis G, Henning RH, de Zeeuw D, van Dokkum RPE: Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rat. *J Am Soc Nephrol* 13: 2909-2915, 2002
44. Gschwend S, Pinto-Sietsma SJ, Buikema H, et al.: Impaired coronary endothelial function in a rat model of spontaneous albuminuria. *Kidney Int* 62: 181-191, 2002
45. Guyton AC, Coleman TG, Cowley AVJ, Scheel KW, Manning RDJ, Norman RAJ: Arterial pressure regulation: Overriding dominance of the kidneys in long-term regulation and in hypertension. *Am J Med* 52: 584-594, 1972
46. Hackbarth H, Gwinner W, Alt JM, Hagemann I, Thiemann A, Finke B: The Munich Wistar Fömtter rat: Proteinuria and blood pressure in correlation to the number of superficial glomeruli. *Ren Physiol Biochem* 14: 146-152, 1991
47. Hayslett LP: Functional adaption to reduction in renal mass. *Physiol Rev* 59: 137-164, 1979
48. Henareh L, Jogestrand T, Agewall S: Microalbuminuria in patients with previous myocardial infarction. *Kidney Int* 69: 178-183, 2005
49. Hessel G: Über Renin. *Klin Wochenschr* 17: 843-849, 1938
50. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. *N Engl J Med* 342: 145-53, 2000
51. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. *Lancet* 355: 253-9, 2000
52. Hostetter TH, Olson JL, Rennke HG, Ventkatachalam MA, BM Brenner: Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. *Am J Physiol* 241 (Renal Fluid Elektrolyte Physiol 10): F85-F93, 1981
53. Howie J, Bliss DJ, Brewer DB: The glomerular ultrastructural distribution of immunoglobulin G in hyperalbuminaemic (protein-overload) proteinuria. *Journal of Pathology* 145: 213-227, 1985
54. Hoy WE, Rees M, Kile E, Mathews JD, Wang Z: A new dimension to the Barker hypothesis: Low birthweight and susceptibility to renal disease. *Kidney Int* 56: 1072-1277, 1999
55. Hsu SI-H, Couser WG: Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: A herapeutic role for complement inhibitors? *J Am Soc Nephrol* 14 (suppl 2): 186-191, 2003

56. Hughson MD, Douglas-Denton R, Bertram JR, Hoy WE: Hypertension, glomerular number, and birth weight in african americans and white subjects in the southeastern united states. *Kidney Int* 69: 671-678, 2006
57. Jackson EK, Garrison JC: Renin and angiotensin. In: Goodman LS, Gilman A, Hardman JG, Limbird LE, Molinoff PB, Ruddon RW: *The pharmacological Basis of Therapeutics*. 9th edition, New York, United States of Amerika, McGraw-Hill: 733-758, 1996
58. Kaufmann K, Hackbarth H: Quantitative vergleichende Untersuchungen zur Bestimmung der Nierenkörperchenanzahl bei der Munich-Wistar-Frömter-Ratte. *Dtsche Tierärztl Wochenschr* 97: 302-304, 1990
59. Kaufman JM, Di Meola HJ, Siegel NJ, Lytton B, Kashgarian M, Hayslett JP: Compensatory adaptation of structure and function following progressive renal ablation. *Kidney Int* 6: 10-7, 1974
60. Keller G, Zimmer G, Mall G, Ritz E, Amann K: Nephron number in patients with primary hypertension. *N Engl J Med* 2: 101-108, 2003
61. Klahr S, Levey AS, Beck GJ, et al.: The effects of dietary protein restriction and blood pressure control on the progression of renal chronic renal disease. Modification of diet in renal disease study group. *N Engl J Med* 330: 877-884, 1994
62. Koletzky S, Goodsitt AM, Cleveland BA: Natural history and pathogenesis of renal ablation hypertension. *Arch Path* 69: 645-662, 1960
63. Kopyt NP: Slowing progression along the renal disease continuum. *J Am Osteopathic Ass* 105: 207-215, 2005
64. Kreutz R, Kovacevic L, Schulz A, Rotermund L, Ketteler M, Paul M: Effect of high NaCl diet on sponanous hypertension in a genetic rat model with reduced nephron number. *J Hypertens* 18: 777-782, 2000
65. Lafayette RA, Mayer G, Park SK, MeyerTW: Angiotensin II blockade limits glomerular injury in rats with reduced renal mass, *J Clin Invest* 90: 766-771, 1992
66. Lee LK, Meyer TW, Pollock AS, Lovett DH: Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. *J Clin Invest* 96: 953-64, 1995
67. Loomis D: Hypertension and necrotizing arteries in the rat following renal infarction. *Arch Pathol* 41: 231-268, 1946
68. Luft FC, Grim CE, Fineberg N, Weinberger MC: Effects of volume expansion and contraction in normotensive whites, blacks, and subjects of different ages. *Circulation* 59: 643-50, 1979
69. Lumbers ER, Yu ZY, Gibson KJ: The selfish brain and the barker hypothesis. *Clin Exp Pharmacol Physiol* 28: 942-947, 2001

70. Macconi D, Ghilardi M, Bonassi ME, et al.: Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. *J Am Soc Nephrol* 11: 477-489, 2000
71. Mackenzie HS, Brenner MD: Fewer nephrons at birth: a missing link in the etiology of essential hypertension. *Am J Kidney Dis* 26: 91-98, 1995
72. Mackenzie HS, Troy JL, Rennke HG, Brenner MD: TCV 116 prevents progressive renal injury in rats with extensive renal mass ablation. *J Hypertens Suppl* 12: 11-6, 1994
73. Manalich R, Reyes L Herrera M, Melendi C, Fundora I: Relationship between weight at birth and the number and size of renal glomeruli in humans: A histomorphometric study. *Kidney Int* 58: 770-773, 2000
74. Mann JFE, Gerstein HC, Yi QL, Lonn EM, et al. for the HOPE investigators: Development of renal disease in people at high cardiovascular risk: Results of the HOPE randomized study. *J Am Soc Nephrol* 14:641-647, 2003
75. Mayer G, Lafayette RA, Oliver J, Deen WM, Myers BD, Meyer TW: Effects of Angiotensin II receptor blockade on remnant glomerular permselectivity. *Kidney Int* 43: 346-353, 1993
76. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. *N Engl J Med* 310: 356 -360, 1984
77. Muntner P, He J, Hamm L, Loria C, Whelton PK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. *J Am Soc Nephrol* 13: 745-753, 2002
78. Nadim MK, Brenner BM: Glomerular normalcy and pathosis: A "fin de millénaire" perspective. *J Nephrol Suppl* 12: 16-28, 1999
79. Nathanielsz WP, Hanson MA: The fetal dilemma: Spare the brain and spoil the liver. *J Physiol* 548: 333, 2003
80. Noble NA, Border WA: Angiotensin II in renal fibrosis: Should TGF-beta rather than blood pressure be the therapeutic target? *Semin Nephrol* 17: 455-66, 1997
81. Nosadini R, Velussi M, Brocco E, et al.: Altered transcapillary escape of albumin and microalbuminuria reflects two different pathogenetic mechanisms. *Diabetes* 54: 228-233, 2005
82. Nyengaard JR, Bendtsen TF: Glomerular number and size in relation to age, kidney weight and body surface in normal man. *Anat Record* 232: 194-201, 1992
83. Olson JL, Hostetter TH, Rennke HG, Brenner BM, Venkatachalam MA: Altered glomerular permselectivity and progressive sclerosis following extreme ablation of renal mass. *Kidney Int* 22: 112-26, 1982

84. Orth SE, Ritz E, Suter-Crazzolara C: Glial cell line-derived neurotrophic factor (GDNF) is expressed in the human kidney and is a growth factor for the human mesangial cells. *Nephrol Dial Transplant* 15: 589-595, 2000
85. Ots M, Troy JL, Rennke HG, Mackenzie HS, Brenner BM: Impact of the supplementation of kidney mass on blood pressure and progression of kidney disease. *Nephrol Dial Transplant* 19: 337-341, 2004
86. Painter RC, Roseboom TJ, van Montfrans GA: Microalbuminuria in adults after exposure to the dutch famine. *J Am Soc Nephrol* 16: 189-194, 2005
87. Paoletti E, Bellino D, Cassottana P, Rolla D, Canella G: Left ventricular hypertrophy in nondiabetic predialysis CKD. *Am J Kidney Dis* 46: 320-7, 2005
88. Paoletti E, Speccia C, Di Maio G et al.: The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: A 10 year survey. *Nephrol Dial Transplant* 19:1829-34, 2004
89. Pelayo JC, Westcott JY: Impaired autoregulation of glomerular capillary hydrostatic pressure in the rat remnant nephron. *J Clin Invest* 88: 101-105, 1991
90. Platt R, Roscoe MH, Smith FW: Experimental renal failure. *Clin Sci* 216: 1, 1952
91. Reichert LJM, Koene RAP, Wetzels JFM: Urinary IgG excretion as a prognostic factor in ideopathic membranous nephropathy. *Clin Nephrol* 48: 79-84, 1997
92. Remuzzi A, Benigini A, Malanchini B, Bruzzi I, Foglieni C, Remuzzi G: ACE inhibition prevents renal failure and death in uninephrectomized MWF/Ztm rats. *Kidney Int* 47: 1319-26, 1995
93. Remuzzi A, Fassi A, Sangalli F, et al.: Prevention of renal injury in diabetic MWF-rats by Angiotensin II antagonism. *Exp Nephrol* 6: 28-38, 1998
94. Remuzzi A, Gagliardini E, Sangalli F, et al.: ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. *Kidney Int*, 69: 1124-30, 2006
95. Remuzzi A, Imberti O, Puntorieri S, et al.: Dissociation between antiproteinuric and antihypertensive effects of angiotensin converting enzyme inhibitors in rats. *Am J Physiol* 267: F1034-44, 1994
96. Remuzzi A, Puntorieri S, Alfano M, Macconi D, Bertani T, Remuzzi G: Pathophysiologic implications of proteinuria in a rat model of progressive glomerular injury. *Lab Invest* 67: 572-579, 1992
97. Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G: Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. *J Clin Invest* 85: 541-549, 1990

98. Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? *Kidney Int* 38: 384–394, 1990
99. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. *N Engl J Med* 339:1448-1456, 1998
100. Remuzzi G, Chiurciu C, Ruggenenti P: Proteinuria predicting outcome in renal disease: Nondiabetic nephropathies. *Kidney Int Suppl* 92: 90-96, 2004
101. Rettig R, Folberth C, Strauss H, Kopf D, Waldherr R, Unger T: Role of the kidney in primary hypertension: A renal transplantation study in rats. *AM J Physiol* 258: F606-611, 1990
102. Riser BL, Cortes P, Zhao X, Bernsein J, Dumler F, Narins RG: Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. *J Clin Invest* 90: 1932-43, 1992
103. Rittinghausen S, Alt J M, Hackbarth H, Messow C: Untersuchungen zur Entwicklung. Nierenmorphologie und Proteinausscheidung bei MWF/Ztm Ratten. *Dtsch Med Wochenschr* 94: 55-8, 1987
104. Ritz E: Hochdruck und Niere - der Beitrag von Franz Volhard. *Dtsch Med Wochenschr* 125: 1411-1415, 2000
105. Rovira-Halbach G, Alt JM, Brunkhorst R, Frei U, Kuhn K, Stolte H: Single nephron hyperfiltration and proteinuria in a newly selected rat strain with superficial glomeruli. *Ren Physiol* 9: 317-25, 1986
106. Sarnak MJ, Levey AS, Schoolwerth AC, et al.: Kidney disease as a risk factor for development of cardiovascular disease. *Circulation* 108: 2154-2169, 2003
107. Schulz AM: Genetische Charakterisierung der MWF-Ratte: Ein Rattenmodell zur Identifizierung genetischer Faktoren, die zu arterieller Hypertonie und Proteinurie führen. Inaugural-Dissertation zur Erlangung der Doktorwürde des Fachbereichs Humanmedizin der Freien Universität Berlin, 2002
108. Sealey JE, Blumenfeld JD, Bell GM, Pecker MS, Sommers SC, Laragh JH: On the renal basis for essential hypertension: Nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. *J Hypertens* 6: 763-777, 1988
109. Shimamura T, Morrison AB: A progressive glomerulosclerosis occurring in partial five-sixths nephrectomy. *Am J Pathol* 79: 95-101, 1975
110. Skov K, Nyengaard J, Korsgaard N, Mulvany MJ: Number and size of renal glomeruli in spontaneously hypertensive rats. *J Hypertens* 12: 1373-6, 1994
111. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ: Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. *Lancet* 340: 319-323, 1992

112. Strauch M, Gretz N: Animal models to induce renal failure: A historical survey. *Contr Nephrol* 60: 1-8, 1988
113. Stuart RO, Bush KT, Nigam SK: Changes in global gene expression patterns during development and maturation of the rat kidney. *Proc Natl Acad Sci USA* 98: 5649-54, 2001
114. United States Renal Data System: USRDS 1997 Annual Data Report, Bethesda, MD, National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, 1998, at <http://www.usrds.org>
115. Vehaskari MV, Aviles DH, Manning J: Prenatal programming of adult hypertension in the rat. *Kidney Int* 59: 238-45, 2001
116. Wang TJ, Evans JC, Meigs JB, Rifai N, Fox CS, D'Agostino RB, Levy D, Vasan RS: Low-grade albuminuria and the risks of hypertension and blood pressure progression. *Circulation* 111: 1370-1376, 2005
117. Zandi-Nejad K, Luyckx VA, Brenner BM: Adult hypertension and kidney disease. The role of fetal programming. *Hypertension* 47: 1-7, 2006
118. Zatz R, Dunn BR, Meyer Tw, et al.: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. *J Clin Invest* 77: 1925-1930, 1986
119. De Zeeuw D, Remuzzi G, Parving HH, et al.: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. *Circulation* 110: 921-7, 2004
120. Zenere BM, Arcaro G, Saggiani F, Rossi L, Muggeo M, Lechi A: Noninvasive detection of functional alterations of the arterial wall in IDDM patients with and without microalbuminuria. *Diabetes Care* 18: 975-982, 1995
121. Zoja C, Remuzzi A, Coma D, Perici N, Bertani T, Remuzzi G: Renal protective effects of angiotensin-converting enzyme inhibition in aging rats. *Am J Med* 279: 60-63, 1992